CXSE3:BMFBOVESPACaixa Seguridade Participacoes SA Analysis
Data as of 2026-03-15 - not real-time
R$18.14
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at R$18.14, comfortably above its 20‑day (R$17.94) and 50‑day (R$17.39) moving averages, confirming a bullish price trajectory, while the RSI of 56.9 indicates neutral momentum and the MACD histogram is slightly negative, hinting at short‑term bearish pressure. Technical analysis shows a modest upside of about 3% to the identified resistance level of R$18.65. Volatility is elevated at 24.6% over the past 30 days, but beta is very low (0.20), suggesting market moves have limited impact on the share.
Fundamentally, CXSE3 trades at a forward P/E of 10.66 versus an industry average of 16.35, and its ROE of 32% and ROA of 20% underscore exceptional profitability; the balance sheet is ultra‑conservative with a debt‑to‑equity of just 0.01. The dividend yield is attractive at 7.23%, yet a payout ratio of 112% raises concerns about sustainability, especially as revenue contracted 6.6% YoY. DCF modeling places fair value near R$15.6, indicating the market price is currently above intrinsic estimates.
Recent news highlights a record profit for 2025 and a 7% year‑over‑year earnings increase, but also points to rising sinistralidade (claims) and results that fell slightly short of analyst forecasts, suggesting pressure on future margins. Combined, the strong earnings power, low leverage, and high dividend appeal are tempered by revenue decline, claim cost escalation, and a price premium to fair value.
Fundamentally, CXSE3 trades at a forward P/E of 10.66 versus an industry average of 16.35, and its ROE of 32% and ROA of 20% underscore exceptional profitability; the balance sheet is ultra‑conservative with a debt‑to‑equity of just 0.01. The dividend yield is attractive at 7.23%, yet a payout ratio of 112% raises concerns about sustainability, especially as revenue contracted 6.6% YoY. DCF modeling places fair value near R$15.6, indicating the market price is currently above intrinsic estimates.
Recent news highlights a record profit for 2025 and a 7% year‑over‑year earnings increase, but also points to rising sinistralidade (claims) and results that fell slightly short of analyst forecasts, suggesting pressure on future margins. Combined, the strong earnings power, low leverage, and high dividend appeal are tempered by revenue decline, claim cost escalation, and a price premium to fair value.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near short‑term resistance with limited upside
- MACD histogram negative signaling bearish momentum
- High dividend yield but unsustainable payout ratio
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Attractive forward P/E versus industry peers
- Strong ROE and ultra‑low leverage
- Record 2025 profit and solid cash generation
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Consistently high profitability and cash flow
- Revenue contraction and rising claim costs
- Regulatory environment and state‑bank ownership stability
Key Metrics & Analysis
Financial Health
Revenue Growth-6.60%
Profit Margin74.80%
P/E Ratio12.7
ROE32.46%
ROA20.18%
Debt/Equity0.01
P/B Ratio4.0
Op. Cash FlowR$4.3B
Free Cash FlowR$3.3B
Industry P/E16.4
Technical Analysis
TrendBullish
RSI56.9
SupportR$0.00
ResistanceR$18.65
MA 20R$17.94
MA 50R$17.39
MA 200R$15.40
MACDBearish
VolumeStable
Fear & Greed Index72.88
Valuation
Fair ValueR$15.62
Target PriceR$18.68
Upside/Downside2.97%
GradeOvervalued
TypeBlend
Dividend Yield7.23%
Risk Assessment
Beta0.20
Volatility24.62%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.